Lung Cancer Clinical Trial

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Summary

The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Stage IIIB or IV Nonsmall cell lung cancer (NSCLC)
No prior chemotherapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 2
Clinically or radiologically measurable disease per RECIST criteria

Exclusion Criteria:

Gastro-intestinal abnormalities
Any concurrent anticancer therapy
Prior treatment with epidermal growth factor receptor (EGFR) inhibitors of any kind
Other active malignancies
Uncontrolled brain metastases
Severe abnormalities of the cornea
Significant cardiac disease

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

103

Study ID:

NCT00085839

Recruitment Status:

Completed

Sponsor:

OSI Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

California Cancer Care, Inc.
Greenbrae California, 94904, United States
Sharp Clinical Oncology Research
San Diego California, 92123, United States
Holy Cross Hospital
Fort Lauderdale Florida, 33308, United States
Mount Sinai Cancer Center
Miami Beach Florida, 33140, United States
University of Miami
Miami Florida, 33136, United States
Evanston Northwestern Healthcare
Evanston Illinois, 60201, United States
Oncology/Hematology Associates of Central Illinois
Peoria Illinois, 61615, United States
Norton Healthcare, Inc.
Louisville Kentucky, 40202, United States
Maryland Hematology/Oncology Associates
Baltimore Maryland, 21237, United States
VA Sierra Nevada Health Care System
Reno Nevada, 89502, United States
Weill Medical College of Cornell University
New York New York, 10021, United States
FEK Addo, PC
Bismarck North Dakota, 58503, United States
Gabrail Cancer Center
Canton Ohio, 44718, United States
University Hospitals of Cleveland
Cleveland Ohio, 44106, United States
Ohio State University
Columbus Ohio, 43210, United States
Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States
Charleston Hematology Oncology
Charleston South Carolina, 29403, United States
East Tennessee Oncology/Hematology, PC
Knoxville Tennessee, 37920, United States
Sarah Cannon Cancer Center
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

103

Study ID:

NCT00085839

Recruitment Status:

Completed

Sponsor:


OSI Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider